Michael Cherny
Stock Analyst at Leerink Partners
(4.29)
# 387
Out of 5,072 analysts
109
Total ratings
59.34%
Success rate
13.62%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Outperform | $203 → $210 | $189.18 | +11.01% | 3 | Oct 21, 2025 | |
| MCK McKesson | Maintains: Outperform | $785 → $850 | $881.12 | -3.53% | 15 | Sep 24, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $188 → $186 | $212.26 | -12.37% | 13 | Aug 12, 2025 | |
| PGNY Progyny | Upgrades: Outperform | $28 | $26.37 | +6.18% | 11 | Jul 8, 2025 | |
| BOLD Boundless Bio | Downgrades: Market Perform | $15 → $3 | $1.16 | +158.62% | 2 | May 28, 2025 | |
| NVST Envista Holdings | Maintains: Buy | $26 → $23 | $20.90 | +10.05% | 11 | Apr 29, 2025 | |
| MEDP Medpace Holdings | Initiates: Market Perform | $330 | $594.28 | -44.47% | 1 | Mar 24, 2025 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $24 → $40 | $39.76 | +0.60% | 10 | Feb 25, 2025 | |
| CVS CVS Health | Upgrades: Outperform | $55 → $75 | $80.36 | -6.67% | 11 | Feb 13, 2025 | |
| DOCS Doximity | Upgrades: Outperform | $60 → $90 | $51.44 | +74.96% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $235 → $280 | $147.19 | +90.23% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $74.57 | +12.65% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $230.01 | +7.82% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $185.00 | +37.84% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.34 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $368.93 | -25.46% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $268.78 | -3.27% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $2.81 | +184.70% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $19 | $9.16 | +107.42% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $7.59 | +123.98% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $2.99 | +1,655.85% | 2 | Jan 5, 2022 |
Quest Diagnostics
Oct 21, 2025
Maintains: Outperform
Price Target: $203 → $210
Current: $189.18
Upside: +11.01%
McKesson
Sep 24, 2025
Maintains: Outperform
Price Target: $785 → $850
Current: $881.12
Upside: -3.53%
Cardinal Health
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $212.26
Upside: -12.37%
Progyny
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $26.37
Upside: +6.18%
Boundless Bio
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.16
Upside: +158.62%
Envista Holdings
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $20.90
Upside: +10.05%
Medpace Holdings
Mar 24, 2025
Initiates: Market Perform
Price Target: $330
Current: $594.28
Upside: -44.47%
Hims & Hers Health
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $39.76
Upside: +0.60%
CVS Health
Feb 13, 2025
Upgrades: Outperform
Price Target: $55 → $75
Current: $80.36
Upside: -6.67%
Doximity
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $51.44
Upside: +74.96%
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $147.19
Upside: +90.23%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $74.57
Upside: +12.65%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $230.01
Upside: +7.82%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $185.00
Upside: +37.84%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $11.34
Upside: -
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $368.93
Upside: -25.46%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $268.78
Upside: -3.27%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $2.81
Upside: +184.70%
Feb 26, 2024
Initiates: Market Perform
Price Target: $19
Current: $9.16
Upside: +107.42%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $7.59
Upside: +123.98%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $2.99
Upside: +1,655.85%